Biomarkers discovered to cisplatin-resistant cancer cells

Scientists at University Paris Descartes in Paris, France, identified biomarkers in non-small cell lung cancer cells that prove resistant to the chemotherapy drug cisplatin. Cells that showed resistance all had high, hyperactivated levels of the protein poly (ADP-ribose) polymerase 1 (PARP1), plus poly (ADP-ribosyl) (PAR). These biomarkers proved themselves even more once the investigators treated cisplatin-resistant non-small cell lung cancer cell lines with two PARP inhibitors--the cancer cells died. "This has clear implications for new treatment regimens and for developing biomarkers of response to cisplatin," researcher Guido Kroemer said in a statement. Details of their work are published in the journal Cancer Research. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.